Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OMP and PwC Alliance Moves Process Manufacturers from Siloed Supply Chain Planning to Unified Decisions23.9.2026 14:25:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / September 23, 2026 / OMP and PwC have formed an alliance to bring unified, faster supply chain decisions to process manufacturers in life sciences, consumer goods, and chemicals. Planning in these industries runs on campaign production, long lead times, and regulatory requirements, all surfacing "too late to act on" when planning sits in separate systems. The alliance combines Unison Planning™, OMP's AI-enabled planning platform with built-in industry expertise, and PwC's implementation services. German specialty pharmaceutical company medac is already live under the alliance, with its planners working on a single demand plan in Unison Planning™. PwC and medac will present the project on October 15, 2026, at the OMP Conference in Singapore, detailing the approach behind the rollout and what it means for planning in pharma. Combining innovation, industry knowledge, and integration OMP and PwC run each implementation as a single program. OMP brings Uniso
SmartVendor Brings Autonomous Retail to the Czech Parliament; Clears Europe's Toughest Privacy Bar with SHEKEL WeightAI(TM)23.9.2026 11:20:00 CEST | Press release
PRAGUE, CZ / ACCESS Newswire / September 23, 2026 / SmartVendor today announced the deployment of an autonomous, AI-powered retail solution inside the Chamber of Deputies of the Parliament of the Czech Republic, built on the WeightAI™ platform from SHEKEL Scales Ltd., the weight-based AI technology and solution provider behind the next generation of autonomous retail. For public institutions across Europe, autonomous retail has presented a compliance contradiction: the technology that makes unattended stores work typically relies on cameras, and cameras mean GDPR risk. The Czech Parliament resolved that contradiction by choosing a solution built on WeightAI™. No cameras. No biometrics. No personal data captured at the point of purchase. Full GDPR compliance by design. The installation, deployed by SmartVendor on the Innovendi Elite platform, marks one of the first deployments of an autonomous AI-powered retail solution inside a major state institution in the Czech Republic. Members of
Fermi and TensorWave Agree to Extend Closing Date to October 31, 202622.9.2026 22:01:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 22, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced that its wholly owned subsidiary, Fermi Campus 1 LLC, and TensorWave TEX1, LLC ("TensorWave") have signed a First Amendment to their Data Center Lease and Services Agreement (the "Lease"). The amendment extends the closing date under the Lease from September 30, 2026 to October 31, 2026. All other terms of the Lease remain unchanged and in effect. The Lease covers 222 megawatts (MW) of total facility power at Fermi's Project Matador campus and represents approximately $6.5 billion in expected total revenue over its initial 15-year term. Parties Working Constructively Toward Closing The Lease, signed in August 2026, provides that its effectiveness is subject to the satisfaction or waiver of specified closing conditions. Those conditions include executing and delivering related work letters and guaranties; finalizing operations sc
Leggett Dynamics Expands Asia Pacific Headquarters22.9.2026 17:00:00 CEST | Press release
SHANGHAI, CHINA / ACCESS Newswire / September 22, 2026 / Leggett Dynamics today celebrated the grand opening of its expanded Asia Pacific headquarters in Shanghai, China marking the latest investment in the company's growth strategy for the region. The expanded facility includes 40 percent more office space, an innovation showroom and multifunctional space for training, events and enhanced collaboration among customers, suppliers and internal teams. "We're not simply expanding our Asia Pacific headquarters in Shanghai. We're expanding our capability to innovate faster, collaborate more closely and create greater value for our customers. This is critical in a hyper competitive market like China which is redefining the user experience in vehicles and turning comfort and motion into the new battleground globally for brand differentiation," said Marinela Cirstea, President of Leggett Dynamics. Today's grand opening in Shanghai reflects Leggett Dynamics' long-term commitment to Asia Pacific
MicroVision Introduces Advanced Photonics Technology for Next-Generation AI Data Center Scale-Up Architecture22.9.2026 15:20:00 CEST | Press release
REDMOND, WA / ACCESS Newswire / September 22, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, security and defense, and automotive applications today announced the introduction by its wholly owned Scantinel subsidiary of an advanced photonics solution designed to address power efficiency and performance challenges critical for next-generation AI data center scale-up architectures and other intelligent infrastructure applications. As the global photonics community gathers in Málaga, Spain this week for the 52nd European Conference on Optical Communication and the Global Photonics Economic Forum, Scantinel revealed its new external laser small form-factor pluggable (ELSFP) module that provides a centralized, serviceable light source for co-packaged optics (CPO) systems in existing and next-generation AI data centers and photonics-enabled AI and cloud infrastructure. Scantinel's differentiated ELSFP technology is built around its core phot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom